CN1231458C - 新的芳氧基－烷基－二烷基胺类化合物 - Google Patents

新的芳氧基－烷基－二烷基胺类化合物 Download PDF

Info

Publication number
CN1231458C
CN1231458C CNB988121492A CN98812149A CN1231458C CN 1231458 C CN1231458 C CN 1231458C CN B988121492 A CNB988121492 A CN B988121492A CN 98812149 A CN98812149 A CN 98812149A CN 1231458 C CN1231458 C CN 1231458C
Authority
CN
China
Prior art keywords
alkyl
compound
halogen
group
alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988121492A
Other languages
English (en)
Chinese (zh)
Other versions
CN1281429A (zh
Inventor
P·拉韦德拉纳特
J·泽尔迪斯
G·维德
J·R·波托斯基
任建新
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/161,653 external-priority patent/US6005102A/en
Application filed by Wyeth LLC, American Home Products Corp filed Critical Wyeth LLC
Publication of CN1281429A publication Critical patent/CN1281429A/zh
Application granted granted Critical
Publication of CN1231458C publication Critical patent/CN1231458C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Detergent Compositions (AREA)
  • Indole Compounds (AREA)
CNB988121492A 1997-10-15 1998-10-14 新的芳氧基－烷基－二烷基胺类化合物 Expired - Fee Related CN1231458C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US95081897A 1997-10-15 1997-10-15
US08/950,818 1997-10-15
US09/161,653 US6005102A (en) 1997-10-15 1998-09-28 Aryloxy-alkyl-dialkylamines
US09/161,653 1998-09-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN 200510118101 Division CN100339371C (zh) 1997-10-15 1998-10-14 新的芳氧基－烷基－二烷基胺类化合物

Publications (2)

Publication Number Publication Date
CN1281429A CN1281429A (zh) 2001-01-24
CN1231458C true CN1231458C (zh) 2005-12-14

Family

ID=26858006

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988121492A Expired - Fee Related CN1231458C (zh) 1997-10-15 1998-10-14 新的芳氧基－烷基－二烷基胺类化合物

Country Status (26)

Country Link
EP (2) EP1777214A3 (enExample)
JP (1) JP2001519410A (enExample)
KR (1) KR100669836B1 (enExample)
CN (1) CN1231458C (enExample)
AR (1) AR015183A1 (enExample)
AT (1) ATE355264T1 (enExample)
AU (1) AU757630C (enExample)
BR (1) BR9813069A (enExample)
CA (1) CA2306343C (enExample)
CY (1) CY1106497T1 (enExample)
DE (1) DE69837210T2 (enExample)
DK (1) DK1025077T3 (enExample)
EA (1) EA003937B1 (enExample)
EE (1) EE200000225A (enExample)
ES (1) ES2281937T3 (enExample)
HU (1) HUP0004419A3 (enExample)
ID (1) ID24417A (enExample)
IL (2) IL135343A0 (enExample)
NO (1) NO20001938L (enExample)
NZ (1) NZ503793A (enExample)
PL (1) PL198443B1 (enExample)
PT (1) PT1025077E (enExample)
SI (1) SI1025077T1 (enExample)
SK (1) SK286460B6 (enExample)
TR (1) TR200001012T2 (enExample)
WO (1) WO1999019293A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20033079B (en) * 1998-05-15 2003-10-27 Wyeth Corp Pharmaceutical Compositions for Treatment of Diseases Caused by Estrogens Deficiency
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
TWI287018B (en) * 1999-09-13 2007-09-21 Wyeth Corp Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
US6376486B1 (en) 2000-07-06 2002-04-23 American Home Products Corporation Methods of inhibiting sphincter incontinence
AU2001273144A1 (en) 2000-07-06 2002-01-21 Wyeth Use of substituted indole compounds for treating neuropeptide y-related conditions
AR029539A1 (es) 2000-07-06 2003-07-02 Wyeth Corp Combinaciones de estatinas y agentes estrogenicos
US6369051B1 (en) 2000-07-06 2002-04-09 American Home Products Corporation Combinations of SSRI and estrogenic agents
WO2002003975A2 (en) 2000-07-06 2002-01-17 Wyeth Combinations of ssri and estrogenic agents
EP1656938A1 (en) 2000-07-06 2006-05-17 Wyeth Combinations of SSRI and estrogenic agents
WO2002003990A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted insole compounds for treating excessive intraocular pressure
US6455568B2 (en) 2000-07-06 2002-09-24 Wyeth Combination therapy for inhibiting sphincter incontinence
AR029538A1 (es) 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
AU2002254114A1 (en) * 2001-03-23 2002-10-08 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
JP2004531559A (ja) 2001-05-22 2004-10-14 イーライ・リリー・アンド・カンパニー エストロゲン欠乏または内因性エストロゲンに対する異常な生理反応に関連する疾患を抑制するためのテトラヒドロキノリン誘導体
WO2002094788A1 (en) 2001-05-22 2002-11-28 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
US7314937B2 (en) 2002-03-21 2008-01-01 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses
US7098241B2 (en) 2002-12-16 2006-08-29 Hoffmann-La Roche Inc. Thiophene hydroxamic acid derivatives
BRPI0509257A (pt) * 2004-04-07 2007-09-11 Wyeth Corp polimorfo cristalino de acetato de bazedoxifeno, composição, processo para preparar um polimorfo e para aumentar a proporção de acetato de bazedoxifeno forma b em uma composição, métodos de tratar um mamìfero, cáncer de mama e uma mulher em pós-menopausa para um ou mais distúrbios vasomotores, de abaixar colesterol e de inibir perda óssea em um mamìfero e uso de um polimorfo
BRPI0509191A (pt) * 2004-04-07 2007-09-25 Wyeth Corp polimorfo cristalino, composição, métodos de preparar forma a polimórfica de acetato de bazedoxifeno, de tratar um mamìfero possuindo uma doença ou sìndrome associada com deficiência de estrogênio ou excesso de estrogênio, e com proliferação ou desenvolvimento anormal de tecidos endometriais, cáncer de mama em um mamìfero, e uma mulher pós-menopausal para um ou vários distúrbios vasomotores, de abaixar colesterol em um mamìfero, e de inibir perda óssea em um mamìfero, e, forma a polimorfa cristalina de acetato de bazedoxifeno
CN1946689A (zh) 2004-04-08 2007-04-11 惠氏公司 作为选择性雌激素受体调节剂的巴西多昔芬抗坏血酸盐
CA2575618A1 (en) * 2004-08-05 2006-02-16 Wyeth Crystalline polymorph of pipindoxifene hydrochloride monohydrate
PE20060874A1 (es) * 2005-01-13 2006-10-16 Wyeth Corp Procedimientos para la preparacion de alcoholes aminoetoxibencilicos
US20100087661A1 (en) * 2007-02-12 2010-04-08 Josef Jirman Method for the preparation of 5-benzyloxy-2-(4-benzyloxphenyl)-3-methyl-1h-indole
US20100016582A1 (en) * 2008-02-11 2010-01-21 Wyeth Methods of converting polymorphic form b of bazedoxifene acetate to polymorphic form a of bazedoxifene acetate
AU2010237209A1 (en) * 2009-04-13 2011-09-01 Sandoz Ag Processes for the synthesis of bazedoxifene acetate and intermediates thereof
US8569483B2 (en) 2011-06-21 2013-10-29 Divi's Laboratories, Ltd. Process for the preparation of bazedoxifene acetate and intermediates thereof
CN104151265B (zh) * 2013-05-13 2016-10-05 上海医药工业研究院 醋酸巴多昔芬中间体的制备方法
WO2014186325A1 (en) 2013-05-15 2014-11-20 Indiana University Research And Technology Corporation Processes and intermediates for preparing indole pharmaceuticals
IT201800006562A1 (it) * 2018-06-21 2019-12-21 Procedimento e intermedi utili per la preparazione di indoli
IT201900001923A1 (it) 2019-02-11 2020-08-11 Erregierre Spa Sali di bazedoxifene utili per la preparazione di bazedoxifene acetato

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH448121A (de) 1963-03-13 1967-12-15 Hoffmann La Roche Verfahren zur Herstellung substituierter Hydrazinverbindungen
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
GB9326332D0 (en) 1993-12-23 1994-02-23 Karo Bio Indole derivatives
IL121202A (en) * 1996-07-01 2001-08-26 Lilly Co Eli Hypoglycemic and hypolipidemic compounds, process for their preparation, pharmaceutial compositions comprising same, and uses thereof
DE69823019T2 (de) * 1997-02-27 2005-03-31 Wyeth Holdings Corp. N-hydroxy-2-(alkyl, aryl oder heteroaryl sulfanyl, sulfinyl oder sulfonyl)-3-substituierte alkyl-, aryl- oder heteroarylamide als matrixmetalloproteinaseinhibitoren
CA2287980A1 (en) * 1997-04-30 1998-11-05 Daniel Jon Sall Antithrombotic agents

Also Published As

Publication number Publication date
WO1999019293A1 (en) 1999-04-22
PL198443B1 (pl) 2008-06-30
AU1083199A (en) 1999-05-03
DE69837210T2 (de) 2007-12-27
AU757630C (en) 2006-10-26
KR100669836B1 (ko) 2007-01-18
HUP0004419A3 (en) 2002-01-28
CN1281429A (zh) 2001-01-24
NO20001938L (no) 2000-06-07
TR200001012T2 (tr) 2000-09-21
KR20010024505A (ko) 2001-03-26
EA200000416A1 (ru) 2000-10-30
ATE355264T1 (de) 2006-03-15
NZ503793A (en) 2002-10-25
AU757630B2 (en) 2003-02-27
EA003937B1 (ru) 2003-10-30
PL339908A1 (en) 2001-01-15
HUP0004419A2 (hu) 2001-07-30
CY1106497T1 (el) 2012-01-25
EP1025077B1 (en) 2007-02-28
BR9813069A (pt) 2000-08-22
CA2306343C (en) 2010-08-03
NO20001938D0 (no) 2000-04-13
AR015183A1 (es) 2001-04-18
EP1777214A3 (en) 2007-05-09
DE69837210D1 (de) 2007-04-12
HK1026889A1 (en) 2000-12-29
EP1777214A2 (en) 2007-04-25
ID24417A (id) 2000-07-20
SI1025077T1 (sl) 2007-06-30
SK5372000A3 (en) 2000-11-07
JP2001519410A (ja) 2001-10-23
IL135343A0 (en) 2001-05-20
SK286460B6 (sk) 2008-10-07
IL135343A (en) 2007-12-03
EE200000225A (et) 2001-06-15
CA2306343A1 (en) 1999-04-22
PT1025077E (pt) 2007-05-31
DK1025077T3 (da) 2007-05-07
ES2281937T3 (es) 2007-10-01
EP1025077A1 (en) 2000-08-09

Similar Documents

Publication Publication Date Title
CN1231458C (zh) 新的芳氧基－烷基－二烷基胺类化合物
US6005102A (en) Aryloxy-alkyl-dialkylamines
CN1230163C (zh) 与雌激素联合的2－苯基－1－[4－(2－氨基乙氧基)－苄基]－吲哚
CN1309384C (zh) 具有5－ht6受体亲和性的4－哌嗪基苯磺酰基吲哚
CN1267423C (zh) 作为ip拮抗剂的取代的2－苯基氨基咪唑啉苯基酮衍生物
CN1263755C (zh) 作为选择性cox－2抑制剂的吡唑并吡啶衍生物
CN1527816A (zh) 新的具有5-ht6受体亲和性的吲哚衍生物
CN1141627A (zh) 用于治疗雌激素相关肿瘤和疾病的新吲哚衍生物
CN1228773A (zh) 杂环金属蛋白酶抑制剂
CN1173956C (zh) 新的哌嗪基烷硫基嘧啶衍生物、含有它的药物组合物和制备该活性物质的方法
CN1281436A (zh) 用于治疗肿瘤的n－苄基－3－茚乙酰胺衍生物
CN1198668A (zh) 萘基和二氢化萘基中间体,化合物,组合物和方法
CN1249025C (zh) 作为IL－1β和TNF－α的抑制剂的氨基二苯酮
CN1875017A (zh) 取代的4－氨基－1－(吡啶基甲基)哌啶化合物的萘－1,5－二磺酸盐
CN1882532A (zh) 氨基烷基酰胺取代的环己基衍生物
CN1803784A (zh) 4－苯基－1－哌嗪基、－哌啶基和－四氢吡啶基衍生物
CN100339371C (zh) 新的芳氧基－烷基－二烷基胺类化合物
CN1481366A (zh) 二氢吲哚和四氢喹啉衍生物
CN1694866A (zh) 具有5－ht6受体亲和力的4－哌嗪基吲哚衍生物
CN1109051A (zh) 3-(苯烷胺基烷氧基)-5-苯基吡唑、制法、中间体及药物
CN1476432A (zh) 吲哚和二氢吲哚衍生物
HK1055960B (en) 4-phenyl-1-piperazinyl, -piperidinyl and - tetrahydropyridyl derivatives
HK1055940A (en) Phenoxybenzylamine derivatives as selective serotonin re-uptake inhibitors
CZ20001368A3 (cs) Aryloxyalkyldialkylaminy
CN1882538A (zh) 作为pai－1抑制剂的取代的磺酰胺－吲哚－2－甲酸衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20051214

Termination date: 20101014